Dynavax GmbH’s Post

We recently announced a Phase 1/2 clinical trial of Z-1018, our investigational vaccine candidate being developed for the prevention of shingles.   Shingles is an extremely painful consequence of the reactivation of a latent varicella-zoster virus infection, the same virus that causes childhood chickenpox, with attacks leading to potential complications including chronic pain. While there are currently approved vaccines for shingles, there is an unmet medical need for a shingles vaccine with both high efficacy and improved tolerability. Read more about the first participant being dosed: https://lnkd.in/gk-nin8d

Good news! Keep contiuning for the next steps!

TWiV 1134: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients. 📺 https://bit.ly/3WFWoqs

TWiV 1140: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID. 📺 https://bit.ly/3X3Wmc9

TWiV 1140: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID. 📺 https://bit.ly/3X3Wmc9

"Lyme disease is a dangerous infection that is endemic to many parts of the USA and Europe. Preventing it with a safe and effective vaccine is an important goal. The phase 2 clinical trials were successful in showing that the vaccine showed strong immunogenicity against Lyme disease bacteria. Also, the studies showed that the vaccine was very safe. Phase 3 clinical trials will have endpoints of preventing Lyme disease and will gather more information about the safety of the vaccine. Although I am not completely certain, I believe that the investigators are still recruiting patients for the phase 3 studies. You can email ClinicalTrials.gov_Inquiries@pfizer.com, to volunteer if you live in the areas being targeted by the trial."

TWiV 1134: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients. 📺 https://bit.ly/3WFWoqs

TWiV 1138: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID. 📺 https://bit.ly/4cgJbJm

TWiV 1138: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID. 📺 https://bit.ly/4cgJbJm

TWiV 1144: Clinical update with Dr. Daniel Griffin 🩺 In his weekly clinical update, Dr. Griffin discusses Dr. Fauci’s case of West Nile virus, polio vaccine campaign develops in Gaza, disease that associates with Oropouche virus, mpox: vaccines, clinical trial for mpox antiviral and the WHO strategic preparedness and response plan before reviewing the recent statistics on SARS-CoV-2 infection, how to obtain free COVID tests, EUA for updated Novavax COVID vaccine, ISDA support of and where to find PEMGARDA, breakthrough infections when administering PEMGARDA, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if nirmatrelvir/ritonavir is effective at preventing hospitalization of high risk patients, incidence of mental illness in the vaccinated and unvaccinated, the effect of amubarvimab/romlusevimab on long COVID outcome, having an evidence based approach to long COVID and how fibrin drives thromboinflammation and neuropathology in COVID-19. 📺 https://bit.ly/4cPRSuu